Glycan and glycosaminoglycans as clinical biomarkers and therapeutics. Part B /
Saved in:
| Imprint: | Cambridge : Academic Press, 2019. |
|---|---|
| Description: | 1 online resource |
| Language: | English |
| Series: | Progress in molecular biology and translational science ; volume 163 Progress in molecular biology and translational science ; v. 163. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/12379405 |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | 12379405 | ||
| 005 | 20200828230742.2 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 190401s2019 mau ob 001 0 eng d | ||
| 015 | |a GBB971900 |2 bnb | ||
| 016 | 7 | |a 019369690 |2 Uk | |
| 019 | |a 1102426035 |a 1103960144 |a 1136267106 |a 1139523628 | ||
| 020 | |a 9780128177396 |q (electronic bk.) | ||
| 020 | |a 012817739X |q (electronic bk.) | ||
| 020 | |a 9780128177419 |q (electronic bk.) | ||
| 020 | |a 0128177411 |q (electronic bk.) | ||
| 020 | |z 9780128177402 |q (print) | ||
| 020 | |z 0128177403 |q (print) | ||
| 035 | |a (OCoLC)1090925584 |z (OCoLC)1102426035 |z (OCoLC)1103960144 |z (OCoLC)1136267106 |z (OCoLC)1139523628 | ||
| 035 | 9 | |a (OCLCCM-CC)1090925584 | |
| 037 | |a 9780128177419 |b Ingram Content Group | ||
| 040 | |a YDX |b eng |e pn |c YDX |d OPELS |d N$T |d EBLCP |d OHS |d OCLCF |d OCLCQ |d OCLCO |d OCLCA |d UKMGB |d UKAHL |d YDXIT |d U3G |d MEU |d OCLCA |d OCLCQ | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a QP702.G577 | |
| 072 | 7 | |a SCI |x 007000 |2 bisacsh | |
| 245 | 0 | 0 | |a Glycan and glycosaminoglycans as clinical biomarkers and therapeutics. |n Part B / |c edited by Lijuan Zhang. |
| 260 | |a Cambridge : |b Academic Press, |c 2019. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent |0 http://id.loc.gov/vocabulary/contentTypes/txt | ||
| 337 | |a computer |b c |2 rdamedia |0 http://id.loc.gov/vocabulary/mediaTypes/c | ||
| 338 | |a online resource |b cr |2 rdacarrier |0 http://id.loc.gov/vocabulary/carriers/cr | ||
| 490 | 1 | |a Progress in molecular biology and translational science ; |v volume 163 | |
| 520 | |a Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases-30 Years Clinical Applications in China, and more. | ||
| 500 | |a Includes index. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Front Cover; Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics -- Part B; Copyright; Contents; Contributors; Preface; Chapter One: Heparin: An essential drug for modern medicine; 1. Introduction; 2. Structure of heparin; 3. The mechanisms of the heparin; 4. Clinical studies of heparin; 4.1. Anti-coagulation activity of heparin; 4.2. Anti-cancer activity of heparin; 4.3. Heparin in inflammatory diseases; 4.4. Heparin in infectious disease; 4.5. Other diseases; 5. Concluding remarks; Acknowledgments; References | |
| 505 | 8 | |a Chapter Two: Low molecular weight heparins and their clinical applications1. Introduction; 2. Structure of LMWHs; 3. Clinical uses of LMWHs; 4. Update on the LMWHs under clinic trials and its potential applications; 4.1. Anti-tumor; 4.2. Anti-viral; 4.3. Anti-inflammation; 4.4. Anti-diabetes-associated complications; 4.5. Other applications; 5. Concluding remarks; Acknowledgments; References; Chapter Three: The clinical use of Fondaparinux: A synthetic heparin pentasaccharide; 1. Structure and mechanism of Fondaparinux; 2. Pharmacokinetics and pharmacodynamics of Fondaparinux | |
| 505 | 8 | |a 3. Clinical application of Fondaparinux3.1. Prophylaxis of VTE; 3.2. Prophylaxis of DVT; 3.3. Other clinical indications; 4. Concluding remarks; Acknowledgments; Conflict of interest; References; Chapter Four: Heparinoids Danaparoid and Sulodexide as clinically used drugs; 1. Heparin and heparinoids; 2. Heparin, low molecular weight heparin, Danaparoid and Sulodexide; 3. Clinical applications of Danaparoid; 3.1. Danaparoid in HIT; 3.2. Danaparoid in DVT; 3.3. Danaparoid in DIC; 4. Clinical applications of Sulodexide; 4.1. Anticoagulant and antithrombotic activity | |
| 505 | 8 | |a 4.2. Prevention of reperfusion injury4.3. Sulodexide in other diseases; 5. Concluding remarks; Acknowledgments; References; Chapter Five: Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond-A review of 31 years clinical exp ... ; 1. Introduction; 2. Preparation, chemical structure, and clinical doses; 3. Clinical uses and efficacy; 4. Adverse reactions; 5. Pharmacodynamics; 6. Pharmacokinetics; 7. Future perspectives; Acknowledgment; Conflicts of interest; References; Chapter Six: Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies | |
| 505 | 8 | |a 1. Introduction2. Preparation and structure of fucoidan; 3. Pharmacology and mechanism of fucoidan; 3.1. Chronic renal failure (CRF); 3.2. Acute kidney injury (AKI); 3.3. Diabetic nephropathy (DN); 4. Clinical uses and efficacy of fucoidan; 5. Future perspectives; Acknowledgments; References; Chapter Seven: Marine glycan-derived therapeutics in China; 1. Introduction; 2. Fucoidan (Haikunshenxi capsules); 2.1. Chemical structure and preparation; 2.2. Pharmacological activities; 2.3. Clinical applications; 3. Chitin ester (PS916); 3.1. Pharmacological activities; 3.2. Pharmacokinetics | |
| 504 | |a Includes bibliographical references and index. | ||
| 650 | 0 | |a Glycomics. |0 http://id.loc.gov/authorities/subjects/sh2003010544 | |
| 650 | 0 | |a Glycoconjugates. |0 http://id.loc.gov/authorities/subjects/sh92001641 | |
| 650 | 0 | |a Biochemical markers. |0 http://id.loc.gov/authorities/subjects/sh85014122 | |
| 650 | 2 | |a Glycomics. | |
| 650 | 2 | |a Glycoconjugates. | |
| 650 | 2 | |a Biomarkers. | |
| 650 | 7 | |a SCIENCE |x Life Sciences |x Biochemistry. |2 bisacsh | |
| 650 | 7 | |a Biochemical markers. |2 fast |0 (OCoLC)fst00831950 | |
| 650 | 7 | |a Glycoconjugates. |2 fast |0 (OCoLC)fst00943768 | |
| 650 | 7 | |a Glycomics. |2 fast |0 (OCoLC)fst00943787 | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Zhang, Lijuan. |0 http://id.loc.gov/authorities/names/n2001089434 |1 http://viaf.org/viaf/249731669 | |
| 776 | 0 | 8 | |i Print version: |z 0128177403 |z 9780128177402 |w (OCoLC)1052874139 |
| 830 | 0 | |a Progress in molecular biology and translational science ; |v v. 163. |0 http://id.loc.gov/authorities/names/no2009049039 | |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i 697f4b80-cb21-53f5-852a-e89b27afa296 |s 824e7a72-871c-5de2-b53a-7afa43de9fba |
| 928 | |t Library of Congress classification |a QP702.G577 |l Online |c UC-FullText |u https://www.sciencedirect.com/science/bookseries/18771173/163 |z Elsevier |g ebooks |i 11979489 | ||